$USAQ
QHSLab, Inc. Stock $usaq

$usaq Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000149315223016675 Filed on May 12, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$404.8K	$352.8K	$355.3K
YoY Change	15.38%	-0.71%	16.75%
Cost Of Revenue	$177.9K	$165.5K	$166.6K
YoY Change	-1.48%	-0.71%	-2.41%
Gross Profit	$226.8K	$187.3K	$188.7K
YoY Change	33.27%	-0.71%	41.26%
Gross Profit Margin	56.04%	53.1%	53.1%
Selling, General & Admin	$184.0K	$226.5K	$202.8K
YoY Change	-24.53%	11.69%	11.54%
% of Gross Profit	81.13%	120.92%	107.48%
Research & Development	$60.52K	$63.55K	$28.98K
YoY Change	3.25%	119.28%	3.43%
% of Gross Profit	26.68%	33.92%	15.36%
Depreciation & Amortization	$36.65K	$36.64K	$18.03K
YoY Change	0.03%	103.24%
% of Gross Profit	16.16%	19.56%	9.56%
Operating Expenses	$262.6K	$308.1K	$249.8K
YoY Change	-18.07%	23.33%	19.06%
Operating Profit	-$35.76K	-$120.8K	-$61.13K
YoY Change	-76.21%	97.54%	-19.83%
Interest Expense	$71.89K	$71.80K	-$127.2K
YoY Change	-44.31%	-156.46%	1119.18%
% of Operating Profit
Other Income/Expense, Net	$920.00
YoY Change
Pretax Income	-$106.7K	-$192.6K	-$190.3K
YoY Change	-61.8%	1.19%	119.52%
Income Tax
% Of Pretax Income
Net Earnings	-$106.7K	-$192.6K	-$190.3K
YoY Change	-61.8%	1.18%	119.53%
Net Earnings / Revenue	-26.37%	-54.58%	-53.56%
Basic Earnings Per Share	-$0.01	-$0.02	-$0.02
Diluted Earnings Per Share	-$0.01	-$0.02	-$21.67K
COMMON SHARES
Basic Shares Outstanding	9.316M shares	9.316M shares	8.780M shares
Diluted Shares Outstanding	9.316M shares	9.316M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$108.9K	$93.08K	$155.6K
YoY Change	12.02%	-40.16%	349.99%
Cash & Equivalents	$108.8K	$93.08K	$155.6K
Short-Term Investments
Other Short-Term Assets	$4.330K	$9.730K	$71.89K
YoY Change	-85.16%	-86.47%	466.51%
Inventory	$34.85K	$27.30K	$73.15K
Prepaid Expenses
Receivables	$101.7K	$76.24K	$96.09K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$249.7K	$206.3K	$396.7K
YoY Change	-14.63%	-47.98%	121.75%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.599M	$1.635M	$1.782M
YoY Change	-8.4%	-8.23%	2941.67%
TOTAL ASSETS
Total Short-Term Assets	$249.7K	$206.3K	$396.7K
Total Long-Term Assets	$1.599M	$1.635M	$1.782M
Total Assets	$1.848M	$1.842M	$2.179M
YoY Change	-9.29%	-15.47%	817.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$202.6K	$187.4K	$33.05K
YoY Change	78.52%	466.98%	-57.56%
Accrued Expenses	$21.48K	$18.99K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$484.5K	$288.4K	$614.0K
YoY Change	48.11%	-53.03%
Long-Term Debt Due	$484.5K	$288.4K	$342.2K
YoY Change	48.11%	-15.73%
Total Short-Term Liabilities	$2.065M	$1.811M	$1.036M
YoY Change	52.62%	74.86%	1047.57%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$141.1K	$457.8K
YoY Change	-100.0%	-69.19%	0.1%
Other Long-Term Liabilities			$8.990K
YoY Change			-92.07%
Total Long-Term Liabilities		$141.1K	$466.8K
YoY Change		-69.78%	-18.21%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.065M	$1.811M	$1.036M
Total Long-Term Liabilities		$141.1K	$466.8K
Total Liabilities	$2.065M	$1.952M	$1.502M
YoY Change	26.82%	29.92%	127.3%
SHAREHOLDERS EQUITY
Retained Earnings	-$3.814M	-$3.707M
YoY Change	27.62%
Common Stock	$932.00	$932.00
YoY Change	5.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$217.0K	-$110.3K	$676.1K
YoY Change
Total Liabilities & Shareholders Equity	$1.848M	$1.842M	$2.179M
YoY Change	-9.29%	-15.47%	817.38%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$106.7K	-$192.6K	-$190.3K
YoY Change	-61.8%	1.18%	119.53%
Depreciation, Depletion And Amortization	$36.65K	$36.64K	$18.03K
YoY Change	0.03%	103.24%
Cash From Operating Activities	-$39.23K	$1.702K	-$137.4K
YoY Change	-199.77%	-101.24%	317.85%
INVESTING ACTIVITIES
Capital Expenditures			-$37.12K
YoY Change			38.1%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change
Cash From Investing Activities	$0.00		-$37.12K
YoY Change			38.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	55.00K	-$87.32K	43.25K
YoY Change	-156.29%	-301.89%
NET CHANGE
Cash From Operating Activities	-39.23K	$1.702K	-137.4K
Cash From Investing Activities	0.000		-37.12K
Cash From Financing Activities	55.00K	-$87.32K	43.25K
Net Change In Cash	15.77K	-$85.62K	-131.3K
YoY Change	-127.01%	-34.79%
FREE CASH FLOW
Cash From Operating Activities	-$39.23K	$1.702K	-$137.4K
Capital Expenditures			-$37.12K
Free Cash Flow			-$100.3K
YoY Change			1569.05%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000856984
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
CY2023Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023Q1	us-gaap	Payments For Software PaymentsForSoftware		usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2023Q1	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt		usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q1	USAQ	Debt And Accrued Interest Converted To Shares Of Common Stock DebtAndAccruedInterestConvertedToSharesOfCommonStock		usd
CY2023Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable		usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable		usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	000-19041
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	QHSLab, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	30-1104301
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	901 Northpoint Parkway
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 302
CY2023Q1	dei	Entity Address Address Line3 EntityAddressAddressLine3	West Palm
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Beach
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33407
CY2023Q1	dei	City Area Code CityAreaCode	(929)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	379-6503
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 Par Value
CY2023Q1	dei	Trading Symbol TradingSymbol	USAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	9315508	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	93079	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	178694	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	76239	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	47734	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	27299	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	51840	usd
CY2023Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	9730	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	7310	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	206347	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	285578	usd
CY2023Q1	us-gaap	Capitalized Software Development Costs For Software Sold To Customers CapitalizedSoftwareDevelopmentCostsForSoftwareSoldToCustomers	148927	usd
CY2022Q4	us-gaap	Capitalized Software Development Costs For Software Sold To Customers CapitalizedSoftwareDevelopmentCostsForSoftwareSoldToCustomers	167543	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1486304	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1504332	usd
CY2023Q1	us-gaap	Assets Assets	1841578	usd
CY2022Q4	us-gaap	Assets Assets	1957453	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	187388	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	85743	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	135849	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	116774	usd
CY2023Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	288396	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	342391	usd
CY2023Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1199195	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1161918	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1810828	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1706826	usd
CY2023Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	141060	usd
CY2022Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	174382	usd
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	141060	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	174382	usd
CY2023Q1	us-gaap	Liabilities Liabilities	1951888	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1881208	usd
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9315508	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9315508	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9315508	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9315508	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	932	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	932	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3595837	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3589837	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3707451	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3514896	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-110310	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	76245	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1841578	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1957453	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	352799	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	355330	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	165457	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	166642	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	187342	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	188688	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	123953	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	113294	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	102572	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	89514	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	63547	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28979	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	18028	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	18028	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	308100	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	249815	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-120758	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-61127	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	71797	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	127157	usd
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2020	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-192555	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-190304	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9315508	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8779859	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	76245	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	6000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-192555	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-110310	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	824066	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	3484	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	27925	usd
CY2022Q1	USAQ	Warrants Issued With Conversion Of Notes Payable WarrantsIssuedWithConversionOfNotesPayable	2020	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	8920	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-190304	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	676111	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-192555	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-190304	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-3641	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	36644	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	18028	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	37277	usd
CY2022Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	96850	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	6000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	8920	usd
CY2022Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	3484	usd
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2020	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	24864	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	25619	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-24541	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7413	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2420	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	49175	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	101645	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	12675	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	19075	usd
CY2022Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-6897	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1702	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-137431	usd
CY2022Q1	us-gaap	Payments For Software PaymentsForSoftware	37119	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-37119	usd
CY2022Q1	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	128500	usd
CY2023Q1	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	87317	usd
CY2022Q1	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	85248	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-87317	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	43252	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-85615	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-131298	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	178694	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	286855	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	93079	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	155557	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	11127	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	18519	usd
CY2022Q1	USAQ	Debt And Accrued Interest Converted To Shares Of Common Stock DebtAndAccruedInterestConvertedToSharesOfCommonStock	27925	usd
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80B_eus-gaap--NatureOfOperations_zFq9JtSWzZtj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1. <span id="xdx_82B_znxu0DQALUJ2">The Company</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">QHSLab, Inc. (f/k/a USA Equities Corp.) (the “Company” or the “Registrant”) was incorporated in Delaware on September 1, 1983<span style="background-color: white">. </span>In 2019, the Company consummated a share exchange agreement with the stockholders of Medical Practice Income, Inc. a Florida corporation (“MPI”). As a result of the acquisition, MPI became a wholly-owned subsidiary of the Company and the Company became engaged in value-based healthcare, informatics and algorithmic personalized medicine including digital therapeutics, behavior based remote patient monitoring, chronic care and preventive medicine. On September 23, 2021, the Company changed its state of incorporation from Delaware to Nevada as a result of a merger with and into its newly formed wholly-owned subsidiary, USA Equities Corp., a Nevada corporation (“USA Equities Nevada”), the surviving entity pursuant to an Agreement and Plan of Merger. USA Equities Nevada is deemed to be the successor to USA Equities Corp., the Delaware corporation. <span style="background-color: white">On April 19, 2022, the Company changed its name to QHSLab, Inc.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is a medical device technology and software-as-a-service (“SaaS”) company focused on enabling primary care physicians (“PCP’s”) to increase their revenues by providing them with relevant, value-based tools to evaluate and treat chronic disease as well as provide preventive care through reimbursable procedures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84F_eus-gaap--UseOfEstimates_zu8TiX2WAJ6k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zYTxYsTlCmr1">Use of Estimates</span>:</i> The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p>
CY2023Q1	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	223390	usd
CY2022Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	223390	usd
CY2023Q1	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	18616	usd
CY2022Q1	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	0	usd
CY2023Q1	us-gaap	Capitalized Computer Software Impairments1 CapitalizedComputerSoftwareImpairments1	0	usd
CY2022	us-gaap	Capitalized Computer Software Impairments1 CapitalizedComputerSoftwareImpairments1	0	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	63547	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28979	usd
CY2023Q1	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	3707451	usd
CY2023Q1	USAQ	Net Operating Losses Carryforwards Expire Date NetOperatingLossesCarryforwardsExpireDate	begin to expire in 2027
CY2023Q1	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	80829	usd
CY2022Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	55964	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	4590	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	8230	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	76239	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	47734	usd
CY2023Q1	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	223390	usd
CY2022Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	223390	usd
CY2023Q1	us-gaap	Capitalized Computer Software Accumulated Amortization CapitalizedComputerSoftwareAccumulatedAmortization	74463	usd
CY2022Q4	us-gaap	Capitalized Computer Software Accumulated Amortization CapitalizedComputerSoftwareAccumulatedAmortization	55847	usd
CY2023Q1	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	148927	usd
CY2022Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	167543	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1612500	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1612500	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	126196	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	108168	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1486304	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1504332	usd
CY2023Q1	us-gaap	Capitalized Computer Software Accumulated Amortization CapitalizedComputerSoftwareAccumulatedAmortization	74463	usd
CY2022Q4	us-gaap	Capitalized Computer Software Accumulated Amortization CapitalizedComputerSoftwareAccumulatedAmortization	55847	usd
CY2023Q1	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	18616	usd
CY2022Q1	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	0	usd
CY2023Q1	us-gaap	Capitalized Computer Software Impairments1 CapitalizedComputerSoftwareImpairments1	0	usd
CY2022	us-gaap	Capitalized Computer Software Impairments1 CapitalizedComputerSoftwareImpairments1	0	usd
CY2021Q2	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	1612500	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	18028	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	18028	usd
CY2023Q1	us-gaap	Debt Default Longterm Debt Amount DebtDefaultLongtermDebtAmount	416279	usd
CY2022Q4	us-gaap	Debt Default Longterm Debt Amount DebtDefaultLongtermDebtAmount	426451	usd
CY2022Q4	us-gaap	Proceeds From Loans ProceedsFromLoans	111300	usd
CY2022Q4	us-gaap	Payments For Loans PaymentsForLoans	13776	usd
CY2022Q4	us-gaap	Loans Payable LoansPayable	93146	usd
CY2023Q1	us-gaap	Loans Payable LoansPayable	26499	usd
CY2023Q1	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	1246000	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	1246000	usd
CY2023Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	46805	usd
CY2022Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	84082	usd
CY2023Q1	USAQ	Convertible Notes Payable Debt Discount And Issuance Costs ConvertibleNotesPayableDebtDiscountAndIssuanceCosts	1199195	usd
CY2022Q4	USAQ	Convertible Notes Payable Debt Discount And Issuance Costs ConvertibleNotesPayableDebtDiscountAndIssuanceCosts	1161918	usd
CY2023Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1199195	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1161918	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.25
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2660747	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2126647	shares
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	6000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	8920	usd
CY2023Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	0	shares
CY2022Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3484	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1100000	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	15900	shares

Files In Submission

Name	View Source	Status
usaq-20230331_def.xml	Edgar Link	unprocessable
0001493152-23-016675-index-headers.html	Edgar Link	pending
0001493152-23-016675-index.html	Edgar Link	pending
0001493152-23-016675.txt	Edgar Link	pending
0001493152-23-016675-xbrl.zip	Edgar Link	pending
ex-31.htm	Edgar Link	pending
ex-32.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
usaq-20230331.xsd	Edgar Link	pending
usaq-20230331_cal.xml	Edgar Link	unprocessable
usaq-20230331_pre.xml	Edgar Link	unprocessable
usaq-20230331_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$USAQ
QHSLab, Inc. Stock $usaq

2023 Q2 Form 10-Q Financial Statement

#000149315223016675 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$USAQ QHSLab, Inc. Stock $usaq

2023 Q2 Form 10-Q Financial Statement

#000149315223016675 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$USAQ
QHSLab, Inc. Stock $usaq